According to the recent research report titled ‘Global Gene Therapy Market - Analysis By Vector Type, By Application, By Region, By Country (2020 Edition): Market Insights, Covid-19 Impact, Competition and Forecast (2020-2025)’, available with MarketStudyReport, global gene therapy market was valued at USD 1221.84 million in 2019 and is expected to record significant growth during 2020-2025.
 

Global gene therapy market growth can be ascribed to companies investing heavily in incorporating advanced technologies, and growing collaboration between bio-pharma companies and research institutes for advancements in the field.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/3056138/
 

Moreover, rising frequency of various diseases, namely sickle cell diseases, Alzheimer’s, neurological disorders, cancer, and cardiovascular ailments, is likely to accelerate the expansion of the overall industry in the future.
 

Based on vector type, the market is split into Lentivirus, AAV, Retrovirus & Gammaretrovirus, and others. Among these, AAV segment is expected to account for significant market share by the year 2025, followed by Retrovirus & Gammaretrovirus and Lentivirus, owing to rising investment in adeno-associated viral (AAV) vectors to promote research against strategically selected cell targets.  
 

With respect to application spectrum, worldwide gene therapy industry segmentation comprises of cancer, neurological disorders, cardiovascular diseases, and others.
 

Elaborating on geographical ambit, North America is anticipated to hold a major market share over the forecast period, followed by Europe and Asia Pacific, owing to presence of several large firms such as Orchard Therapeutics, Voyager Therapeutics, and Spark Therapeutics in the region.  
 

Companies investing in innovative technologies, together with manufacturers' focus on extending product pipelines to advance in the field of gene therapy, will aid the regional market expansion over the projection period.
 

Coming to competitive landscape, AnGes Inc., MoldMed S.p.A., Novartis AG, Orchard Therapeutics plc, Voyager Therapeutics, Spark Therapeutics Inc., Alnylam Pharmaceuticals Inc., Akcea Therapeutics Inc., BlueBird Bio Inc., and Sarepta Therapeutics Inc. are the leading companies powering global gene therapy market dynamics.
 

The critical findings of the report are presented through the framework of major mergers and acquisitions, technological innovations, and companies' roles during the COVID-19 pandemic, as well as a product pipeline of leading companies.